IL6 and chronic myelogenous leukemia, BCR-ABL1 positive: However, while the results from the present study align with the majority of studies confirming the detrimental signaling promoted by elevated levels of IL-6, another study demonstrated that low levels of IL-6 are associated with an 8-fold higher risk of relapse in patients in treatment-free remission (TFR) of CML [37].